Thrombopoietin receptor agonists (TPO-RAs) are a class of subsequent-line therapy used in patients with ITP that exert therapeutic effects mainly by stimulating platelet production in the bone marrow [14]. The gene discussed is MPL; the disease is autoimmune thrombocytopenic purpura.